EPS for Oramed Pharmaceuticals Inc. (ORMP) Expected At $-0.24

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo
Investors sentiment decreased to 1.33 in 2018 Q4. Its down 2.67, from 4 in 2018Q3. It turned negative, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 4 reduced holdings. 3 funds opened positions while 5 raised stakes. 1.80 million shares or 47.09% less from 3.40 million shares in 2018Q3 were reported.
28,394 are owned by Morgan Stanley. Blackrock reported 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Northern Tru accumulated 18,269 shares. Renaissance Lc has 58,528 shares for 0% of their portfolio. National Bank & Trust Of Montreal Can reported 1,600 shares. Glenmede Tru Na reported 20,000 shares. Nordea Inv Management accumulated 500 shares. Jfs Wealth Advsrs Lc stated it has 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). State Bank Of America De accumulated 1,117 shares. Panagora Asset Mgmt reported 9,259 shares stake. 1,500 were reported by Royal Retail Bank Of Canada. Dafna Limited Liability Co stated it has 0.02% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The Pennsylvania-based Pnc Financial Svcs has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Barclays Public Ltd accumulated 41,186 shares. Sabby Mngmt Ltd Liability Corp holds 933,050 shares or 0.62% of its portfolio.

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.24 EPS on April, 8.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. The stock increased 1.57% or $0.05 during the last trading session, reaching $3.23. About 6,831 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 54.70% since March 17, 2018 and is downtrending. It has underperformed by 59.07% the S&P500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $56.13 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Seekingalpha.com which released: “The Math Behind Oramed’s Oral Insulin Suggests It’s Economically Viable – Seeking Alpha” on February 20, 2019, also Seekingalpha.com with their article: “Oramed on go to start clinical trials on ORMD-0901 – Seeking Alpha” published on September 17, 2018, Streetinsider.com published: “Oramed Pharma (ORMP) Commences Phase I Oral GLP-1 Study Under IND – StreetInsider.com” on January 22, 2019. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Streetinsider.com and their article: “Oramed Pharma (ORMP) Announces FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule – StreetInsider.com” published on September 17, 2018 as well as Prnewswire.com‘s news article titled: “Oramed Pharmaceuticals’ CEO Letter to Shareholders – PRNewswire” with publication date: January 15, 2019.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.